FDA to Hold Call Discussing Potential Issues with Pfizer's (PFE) Stop-Smoking Drug, Chantix -CNBC
More News related to PFE
- Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
- Emerging Healthcare in Discussions with Genetics Leader
- Pfizer To Present Clinical Data From Expanded Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium
- Hapoalim Securities Reiterates a 'Buy' on Protalix (PLX); Raises PT in Wake of Pfizer (PFE) Deal
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
According to CNBC's Mike Huckman, a Pfizer (NYSE: PFE) spokesperson has said that the FDA will hold a 12:30pm ET call related to the possible issues of the company's stop-smoking drug, Chantix.
Related Categories
FDARumors
Stocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
